Skip to content

Study · Non-randomized trial · n = 27 · 2007

4 results

[The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax].

Serdiuk AV, Levitskiĭ GN, Miasoedov NF, Skvortsova VI

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2007Cited by 2 (Europe PMC)

PMID18379501 (opens in a new tab)PepBankPUB-18379501
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with motor neuron disease, 1% semax did not influence the course of chronic partial denervation.

    In plain wordsIn people with motor neuron disease, 1% semax did not change the course of nerve loss in the muscles.

    Peptide
    Semax
    Outcome
    No significant changeCourse of chronic partial denervation (needle EMG)
    Study

    n = 27

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    12 mg daily · intranasal · two 10-day courses with 2-week breakAs given in this study (human).

    Source sentences

    Summary
    Semax (1% solution) does not influence either the course of CPD
    2 context sentences
    Summary · context
    The study of chronic partial denervation (CPD) and quality of life was carried out in 27 patients with definite, probable and possible diagnosis of motor neuron disease (MND) treated with semax (1% solution).
    Summary · context
    The drug was administered intranasally in two 10-day-long courses with 2-weeks break in daily dose of 12 mg.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with motor neuron disease, 1% semax did not influence the dynamics of clinical estimates, including the time to marked functional deficits.

    In plain wordsIn people with motor neuron disease, 1% semax did not change the course of clinical scores or the time to marked loss of function.

    Peptide
    Semax
    Outcome
    No significant changeDynamics of clinical estimates (ALS scales)
    Study

    n = 27

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    12 mg daily · intranasal · two 10-day courses with 2-week breakAs given in this study (human).

    Source sentences

    Summary
    Semax (1% solution) does not influence either the course of CPD or the dynamics of clinical estimates, in particular the terms of ensuing marked functional deficits on bulbar, cervical and lumbosacral levels of segmental innervation.
    2 context sentences
    Summary · context
    The study of chronic partial denervation (CPD) and quality of life was carried out in 27 patients with definite, probable and possible diagnosis of motor neuron disease (MND) treated with semax (1% solution).
    Summary · context
    The drug was administered intranasally in two 10-day-long courses with 2-weeks break in daily dose of 12 mg.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with motor neuron disease, 1% semax significantly improved the total estimate of life quality, with the maximal effect on day 10.

    In plain wordsIn people with motor neuron disease, 1% semax improved the overall quality of life score, with the largest effect on day 10.

    Peptide
    Semax
    Outcome
    IncreaseTotal estimate of life quality (ALSAQ-40)
    Study

    n = 27

    Outcome group
    Quality of life · Nervous system and cognition
    Studied dose
    12 mg daily · intranasal · two 10-day courses with 2-week breakAs given in this study (human).

    Measurements

    Peak effect day
    10 day
    total quality of life

    Source sentences

    Summary
    However, 1% semax significantly improves the total estimate of life quality due to the improvement of emotional state and motivation in MND patients with the maximal effect on day 10.
    2 context sentences
    Summary · context
    The study of chronic partial denervation (CPD) and quality of life was carried out in 27 patients with definite, probable and possible diagnosis of motor neuron disease (MND) treated with semax (1% solution).
    Summary · context
    The drug was administered intranasally in two 10-day-long courses with 2-weeks break in daily dose of 12 mg.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with motor neuron disease, 1% semax improved emotional state and motivation, which drove the gain in life quality.

    In plain wordsIn people with motor neuron disease, 1% semax improved emotional state and motivation.

    Peptide
    Semax
    Outcome
    IncreaseEmotional state and motivation
    Study

    n = 27

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    12 mg daily · intranasal · two 10-day courses with 2-week breakAs given in this study (human).

    Source sentences

    Summary
    However, 1% semax significantly improves the total estimate of life quality due to the improvement of emotional state and motivation in MND patients with the maximal effect on day 10.
    2 context sentences
    Summary · context
    The study of chronic partial denervation (CPD) and quality of life was carried out in 27 patients with definite, probable and possible diagnosis of motor neuron disease (MND) treated with semax (1% solution).
    Summary · context
    The drug was administered intranasally in two 10-day-long courses with 2-weeks break in daily dose of 12 mg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.